Powder: -20°C for 3 years | In solvent: -80°C for 1 year
C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo. It also activates NF-κB production in C6 glioma cells when used at a concentration of 10 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | Inquiry | $ 777.00 |
Description | C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo. It also activates NF-κB production in C6 glioma cells when used at a concentration of 10 μM. |
Synonyms | C8 Galactosylceramide (d18:1/8:0) |
Molecular Weight | 587.83 |
Formula | C32H61NO8 |
CAS No. | 41613-16-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
C8 Galactosylceramide (d18:1/8:0) 41613-16-5 C-8 Galactosylceramide (d18:1/8:0) C8 Galactosylceramide d18:1/8:0 inhibitor inhibit